Marshall Wace, LLP Nuvation Bio Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 209,999 shares of NUVB stock, worth $1.02 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
209,999
Previous 871,190
75.9%
Holding current value
$1.02 Million
Previous $1.7 Million
54.3%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding NUVB
# of Institutions
217Shares Held
165MCall Options Held
1.99MPut Options Held
660K-
Decheng Capital LLC Menlo Park, CA26MShares$126 Million16.75% of portfolio
-
Black Rock Inc. New York, NY16.2MShares$78.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.5MShares$75.1 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY9.71MShares$47.2 Million0.67% of portfolio
-
Omega Fund Management, LLC Boston, MA8.83MShares$42.9 Million89.01% of portfolio
About Nuvation Bio Inc.
- Ticker NUVB
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 217,244,000
- Market Cap $1.06B
- Description
- Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...